Epidermal growth factor receptor biology in head and neck cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2005.04.8306PMID 16763281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of the cell-cell adhesion molecule E-cadherin in squamous cell carcinoma of the head and neck.

  2007cited by this paper
• Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis*

  2005cited by this paper
• Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.

  2005cited by this paper
• GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways

  2005cited by this paper
• Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.

  2005cited by this paper
• Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.

  2005cited by this paper
• Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer

  2005cited by this paper
• Biological significance of c-erbB family oncogenes in head and neck cancer

  2005cited by this paper
• HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.

  2005cited by this paper
• Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands.

  2005cited by this paper
• Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

  2005cited by this paper
• Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor.

  2005cited by this paper
• Prostaglandin E2 and Bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms.

  2005cited by this paper
• Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism.

  2005cited by this paper
• Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR

  2005cited by this paper
• Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors

  2005cited by this paper
• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

  2005cited by this paper
• Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.

  2005cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005cited by this paper
• The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade

  2005cited by this paper
• Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

  2005cited by this paper
• Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.

  2005cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

  2004cited by this paper
• Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor.

  2004cited by this paper
• An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

  2004cited by this paper
• Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck

  2004cited by this paper
• Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.

  2004cited by this paper
• Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor.

  2004cited by this paper
• Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells

  2004cited by this paper
• Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

  2004cited by this paper
• Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells

  2004cited by this paper
• Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Signaling through the epidermal growth factor receptor during the development of malignancy.

  2004cited by this paper
• Pharmacodiagnostic Value of the HER Family in Head and Neck Squamous Cell Carcinoma

  2004cited by this paper
• Mini ReviewSignalling by the Type 1 Insulin-like Growth Factor Receptor: Interplay with the Epidermal Growth Factor Receptor

  2004cited by this paper
• Epidermal Growth Factor Receptor-stimulated Activation of Phospholipase Cγ-1 Promotes Invasion of Head and Neck Squamous Cell Carcinoma

  2003cited by this paper
• Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor*

  2003cited by this paper
• The ErbB receptors and their role in cancer progression.

  2003cited by this paper
• STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor*

  2003cited by this paper
• TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells

  2003cited by this paper
• Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor

  2003cited by this paper
• Constitutive activation of Stat5b contributes to carcinogenesis in vivo.

  2003cited by this paper
• Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis.

  2003cited by this paper
• Nuclear localization and possible functions of receptor tyrosine kinases.

  2003cited by this paper
• Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.

  2003cited by this paper
• NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer

  2002cited by this paper
• EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.

  2002cited by this paper
• The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

  2002cited by this paper
• Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

  2002cited by this paper
• NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

  2002cited by this paper
• Mutant epidermal growth factor receptors as targets for cancer therapy.

  2002cited by this paper
• STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.

  2002cited by this paper
• EGF/ErbB receptor family in ovarian cancer.

  2002cited by this paper
• Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines*

  2002cited by this paper
• Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions.

  2001cited by this paper
• The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

  2001cited by this paper
• Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking.

  2001cited by this paper
• Nuclear localization of EGF receptor and its potential new role as a transcription factor

  2001cited by this paper
• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  2001cited by this paper
• Co‐localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma

  2001cited by this paper
• Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

  2001cited by this paper
• Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.

  2000cited by this paper
• Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*

  2000cited by this paper
• Signaling from E-cadherins to the MAPK Pathway by the Recruitment and Activation of Epidermal Growth Factor Receptors upon Cell-Cell Contact Formation*

  2000cited by this paper
• Expression and regulation of c‐erbB ligands in human head and neck squamous carcinoma cells

  2000cited by this paper
• ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors*

  1999cited by this paper
• Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers.

  1999cited by this paper
• Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.

  1998cited by this paper
• Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.

  1998cited by this paper
• Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

  1998cited by this paper
• Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell.

  1998cited by this paper
• Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.

  1997cited by this paper
• Vascular endothelial growth factor expression in head and neck squamous cell carcinoma.

  1997cited by this paper
• MYC amplification in squamous cell carcinomas of the head and neck.

  1996cited by this paper
• High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.

  1996cited by this paper
• Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

  1994cited by this paper
• Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma.

  1994cited by this paper
• Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

  1993cited by this paper
• The incidence of p53 mutations increases with progression of head and neck cancer.

  1993cited by this paper

• Signaling pathways and potential therapeutic agents in trastuzumab-induced cardiotoxicity

  2026cites this paper
• Use of Dual-Modality Antibody Imaging for Assessment of Lymph Node Metastases in Head and Neck Cancer

  2026cites this paper
• EGFRvIII expression in head and neck squamous cell carcinoma: clinical significance and sources of frequency variation across studies

  2026cites this paper
• Novel Immunotherapeutic Approaches for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma

  2026cites this paper
• Beyond EGFR inhibition in Head and Neck Squamous Cell Carcinoma: overcoming resistance mechanisms and novel therapeutic frontiers.

  2026cites this paper
• Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 study

  2026cites this paper
• Bridging cancer cell-intrinsic driver genes and -extrinsic cell-cell communication with Driver2Comm.

  2026cites this paper
• A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma.

  2026cites this paper
• Recent knowledge on squamous cell carcinoma of the oral cavity: Contributing factors, underlying molecular pathways, and current attitudes in the therapeutic approaches

  2025cites this paper
• Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early‐Stage Squamous Cell Carcinoma of the Head and Neck: Long‐Term Follow‐Up

  2025cites this paper
• Current Challenges and Potential Opportunities for Interception and Prevention of Head and Neck Cancer.

  2025cites this paper
• ANXA1 binds and stabilizes EGFR to promote nasopharyngeal carcinoma radioresistance.

  2025cites this paper
• Subtype-Specific Dependencies and Drug Vulnerabilities Enable Precision Therapeutics in Head and Neck Cancer

  2025cites this paper
• Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

  2025cites this paper
• PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma

  2025cites this paper
• Cancer Stem Cell Mechanisms and Targeted Therapeutic Strategies in Head and Neck Squamous Cell Carcinoma.

  2025cites this paper
• Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review.

  2025cites this paper
• CRISPR Screens Identify PIK3C2A as a Novel Mediator of EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Epidermal Growth Factor Receptor (EGFR) membranous and cytoplasmic overexpression on immunohistochemistry: An additional prognostic marker in oral squamous cell carcinoma.

  2025cites this paper
• Exploring Cu-catalyzed intramolecular cyclization for the synthesis of benzimidazo-pyrrolo[3,4-b]pyridines: In silico, DFT and in vitro anti-lung cancer study

  2025cites this paper
• RBM24 regulates apoptosis rates by modulating global transcriptome profile in CAL27 cells

  2025cites this paper
• Predictive Value of EGFR Expression for the Efficacy of Near-Infrared Photoimmunotherapy in Head and Neck Cancer

  2025influential citation
• Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

  2025cites this paper
• Targeted siRNA Delivery Using Cetuximab‐Conjugated Starch for Epidermal Growth Factor Receptor‐Driven Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Novel Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Beyond EGFR and Checkpoint Blockade

  2025cites this paper
• A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

  2025cites this paper
• Durable complete response to tislelizumab plus cetuximab in a 94-year-old patient with advanced lower lip squamous cell carcinoma: A case report and literature review.

  2025cites this paper
• Background Tissue with Native Target Expression Can Determine Presence of Nodal Metastasis in Head and Neck Squamous Cell Carcinoma Patients Infused with Targeted Fluorescent Tracers

  2025cites this paper
• Pyrazoline B Induces Oxidative Stress Mediated Toxicity, Cell Cycle Arrest, and Caspase-Independent Apoptosis in BT-474 Human Breast Cancer Cells

  2025cites this paper
• Nimotuzumab in Combination with Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinoma Cancer Patients: A Single-Arm Observational Study

  2025cites this paper
• LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer

  2025cites this paper
• Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy

  2025cites this paper
• MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Emerging and Investigational Systemic Therapies in Recurrent/Metastatic Head and Neck Cancer After Progression on Immunotherapy

  2025cites this paper
• Near-infrared photoimmunotherapy: basics and clinical application.

  2025cites this paper
• Shaping viral immunotherapy towards cancer-targeted immunological cell death

  2025cites this paper
• Circulating Tumor Cells in Head and Neck Squamous-Cell Carcinoma Exhibit Distinct Properties Based on Targeted Epithelial-Related Markers

  2025cites this paper
• The mechanisms of environmental pollutant acetyl tributyl citrate induced oral squamous cell carcinoma using network toxicology, molecular docking and molecular dynamics simulation

  2025cites this paper
• Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms

  2025influential citation
• FER kinase governs invasive growth of head and neck squamous cell carcinoma through dynamic control of growth factor receptor activity

  2025cites this paper
• Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials

  2024cites this paper
• Ex vivo detection of oral squamous cell carcinoma spread to lymph nodes using paired-agent fluorescence optical tomography: path to clinical translation

  2024cites this paper
• Photoimmunotheranostics of epithelioid sarcoma by targeting CD44 or EGFR.

  2024cites this paper
• Expression of epithelial growth factor receptor as a protein marker in oral reticular and erosive lichen planus

  2024cites this paper
• Deciphering genomic complexity: Understanding intratumor heterogeneity, clonal evolution, and therapeutic vulnerabilities in oral squamous cell carcinoma

  2024cites this paper
• Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study

  2024cites this paper
• Pan-cancer molecular signatures connecting aspartate transaminase (AST) to cancer prognosis, metabolic and immune signatures

  2024cites this paper
• Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review).

  2024cites this paper
• An epidermal growth factor receptor‐targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer

  2024cites this paper
• Federated Deep Learning Enables Cancer Subtyping by Proteomics

  2024cites this paper
• Combination Effect of Radiotherapy and Targeted Therapy with NK Cell-Based Immunotherapy in head and Neck Squamous Cell Carcinoma

  2024cites this paper
• Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer

  2024cites this paper
• Chemopreventive and Biological Strategies in the Management of Oral Potentially Malignant and Malignant Disorders

  2024cites this paper
• Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck Cancers

  2024cites this paper
• Research Progress on the Role of EGFR in Tumorigenesis, Development and Treatment

  2024cites this paper
• Anti-EGFR antibody immunotoxins improve cytotoxic effects in the salivary gland cancer A253 cell line

  2024cites this paper
• Identification of novel therapeutic targets for head and neck squamous cell carcinoma through bioinformatics analysis

  2024cites this paper
• The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

  2024cites this paper
• Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer

  2024cites this paper
• Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review

  2024cites this paper
• Lapatinib-induced enhancement of mitochondrial respiration in HER2-positive SK-BR-3 cells: mechanism revealed by analysis of proteomic but not transcriptomic data

  2024cites this paper
• Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway

  2024cites this paper
• Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy—a review

  2024cites this paper
• What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas—Current Status and Future Directions?

  2024cites this paper
• A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

  2024cites this paper
• Effect of Degree of Substitution and Molecular Weight on Transfection Efficacy of Starch-Based siRNA Delivery System

  2024cites this paper
• Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

  2024cites this paper
• Improved ex vivo fluorescence imaging of human head and neck cancer using the peptide tracer TPP-IRDye800 targeting membrane-bound Hsp70 on tumor cells

  2024cites this paper
• Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to target squamous cell cancers with tyrosine kinase inhibitors.

  2024cites this paper
• Expression of p16INK4a, FLOT2, and EGFR in oropharyngeal carcinoma, prognostic significance and correlation with clinicopathological characteristics

  2024influential citation
• Use of Geftinib and Methotrexate in Residual Cases of Squamous Cell Carcinoma of Head and Neck after Radical Treatment

  2023cites this paper
• Targeted therapy for head and neck cancer: signaling pathways and clinical studies

  2023cites this paper
• Signalling-state dependent drug-tolerance in head and neck squamous cell carcinoma

  2023cites this paper
• Metabolic Patterns of High-Invasive and Low-Invasive Oral Squamous Cell Carcinoma Cells Using Quantitative Metabolomics and 13C-Glucose Tracing

  2023cites this paper
• Tobacco Cessation Following Laryngeal Cancer Diagnosis Predicts Response to Treatment and Laryngectomy-Free Survival.

  2023cites this paper
• Anti-EGFR bioengineered bacterial outer membrane vesicles as targeted immunotherapy candidate in triple-negative breast tumor murine model

  2023cites this paper
• Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

  2023cites this paper
• Fibromodulin overexpression drives oral squamous cell carcinoma via activating downstream EGFR signaling

  2023cites this paper
• Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma

  2023cites this paper
• RNA‐binding protein‐regulated fibronectin is essential for EGFR‐activated metastasis of head and neck squamous cell carcinoma

  2023cites this paper
• Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer.

  2023cites this paper
• The effect of P53 expression and smoking/alcohol in P16(+) and P16(-) oropharyngeal carcinoma and risk classification: the Turkish Society of Radiation Oncology Head & Neck Study Group 01-002.

  2023cites this paper
• A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma.

  2023cites this paper
• A Novel Germline Pathogenic Variant of RECQL4 Gene in an Iranian Pedigree with Familial Squamous Cell Carcinoma: A Brief Report

  2023cites this paper
• Memory-like differentiation, tumor targeting monoclonal antibodies, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer.

  2023cites this paper
• Nuclear Epidermal Growth Factor Receptor Overexpression as a Survival Predictor in Oral Squamous Cell Carcinoma

  2023cites this paper
• Erk1/2-Dependent HNSCC Cell Susceptibility to Erastin-Induced Ferroptosis

  2023cites this paper
• Chemoprevention of oral cancer: A review and future perspectives

  2023influential citation
• Advanced Techniques in Head and Neck Cancer Imaging: Guide to Precision Cancer Management.

  2023cites this paper
• NAD pool as an antitumor target against cancer stem cells in head and neck cancer

  2023cites this paper
• Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment

  2023cites this paper
• Combination treatment of arsenic trioxide and osimertinib in recurrent and metastatic head and neck squamous cell carcinoma.

  2022cites this paper
• Targeting HRAS in Head and Neck Cancer

  2022cites this paper
• FUT6 inhibits the proliferation, migration, invasion, and EGF-induced EMT of head and neck squamous cell carcinoma (HNSCC) by regulating EGFR/ERK/STAT signaling pathway

  2022cites this paper
• One hundred most‐cited articles in head and neck surgery and analysis of female authorship

  2022cites this paper
• Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor.

  2022cites this paper
• In vitro models for head and neck cancer: Current status and future perspective

  2022cites this paper
• Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology

  2022cites this paper
• Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma

  2022cites this paper
• Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival.

  2022cites this paper